12:00 AM
Dec 18, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HuMax-CD4: Began Phase II trials

Genmab A/S (CSE:GEN; NMarkt:GE9D), Brondby, Denmark
Product: HuMax-CD4
Business: Autoimmune/Inflammation
Therapeutic category: Antibody, Immune suppression
Target: CD4

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >